Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of death among people with cancer, with little advance in treatment over decades. While the incidence of PDAC is gradually increasing every year, the survival rate of peope with PDAC at 5 years is very low (less than 1% in 2011, and now it is still far below 10%), making PDAC as one of the most difficult to treat cancers. 

PDAC is protected by the thick fibrous tissues, preventing cancer cells from drug exposure or immune cell invasion. Bi-Path Bio found a breakthrough to attack cancer cells by our innovative idea